PDF(Pubmed)
Abstract：
Perampanel belongs to a novel class of antiseizure medications (ASMs). Studies examining the effect of hemodialysis on perampanel serum levels in clinical settings are lacking. We aimed to evaluate the changes in serum perampanel levels during hemodialysis. We studied patients with seizures who received oral perampanel between April 2020 and March 2023 and whose serum concentration of perampanel was measured before and after hemodialysis. We analyzed the serum concentrations of levetiracetam and lacosamide for comparison. Fourteen patients, with a mean age of 76.1 ± 7.88 years, were included. The dose of perampanel was 2.14 ± 1.27 mg. The hemodialysis clearance rate of perampanel, levetiracetam, and lacosamide was 0 ± 13%, 69 ± 11%, and 59.6 ± 8.2%, respectively. The post-dialysis CD ratio decreased significantly with levetiracetam but not with perampanel. Adverse but acceptable effects of perampanel were observed in two patients. The serum concentrations of several ASMs have been shown to be reduced during hemodialysis. Our study revealed that the serum perampanel concentration does not decrease during hemodialysis. Owing to the low rate of adverse effects and the stability of perampanel serum concentration during hemodialysis, perampanel could be a favorable choice as an ASM for patients with seizures undergoing hemodialysis. PLAIN LANGUAGE SUMMARY: Our study looked at how hemodialysis affects the serum levels of perampanel, a new type of medication for seizures. In 14 patients who started treatment between April 2020 and March 2023, perampanel serum levels did not decrease during hemodialysis, unlike other seizure medications. This shows that perampanel can be a good option for patients with seizures who need hemodialysis, with fewer side effects compared to other medications.
摘要：
Perampanel属于一类新型的抗癫痫药物（ASM）。缺乏在临床环境中检查血液透析对perampanel血清水平影响的研究。我们旨在评估血液透析过程中血清潘帕内水平的变化。我们研究了在2020年4月至2023年3月期间接受口服perampanel的癫痫患者，并在血液透析前后测量了其血清perampanel浓度。我们分析了左乙拉西坦和拉科沙胺的血清浓度以进行比较。十四个病人,平均年龄为76.1±7.88岁，包括在内。perampanel的剂量为2.14±1.27mg。perampanel的血液透析清除率，左乙拉西坦,拉科沙胺为0±13%，69±11%，和59.6±8.2％，分别。左乙拉西坦组的透析后CD比率显着降低，而perampanel组则没有。在两名患者中观察到perampanel的不良但可接受的效果。已显示在血液透析期间几种ASM的血清浓度降低。我们的研究表明，血液透析期间血清perampanel浓度不会降低。由于血液透析过程中不良反应发生率低和血药浓度稳定，对于接受血液透析的癫痫患者，Perampanel可能是ASM的有利选择。PLAINLANGUAGE总结：我们的研究观察了血液透析如何影响perampanel的血清水平，一种治疗癫痫的新型药物.在2020年4月至2023年3月期间开始治疗的14名患者中，血液透析期间的perampanel血清水平没有下降，与其他癫痫药物不同。这表明，对于需要血液透析的癫痫患者来说，perampanel是一个很好的选择，与其他药物相比副作用更少。
